Drug Discovery World

SEPTEMBER 7, 2022

The PROfound trial, led by researchers at the ICR and The Royal Marsden NHS Foundation Trust, showed that in men with faulty DNA repair genes olaparib blocked prostate cancer growth more effectively than modern hormone treatments. Biomarker testing “should be routine”.

Genetics 52

Genetics Drugs DNA Gene 52

Drug Discovery World

APRIL 4, 2023

The decision will enable the company to include the US in the global Phase II portion of its ongoing Phase I/II study of NTLA-2002, an in vivo genome editing candidate designed to inactivate the target gene, kallikrein B1 (KLKB1).

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

Delveinsight

DECEMBER 7, 2020

In May 2020, Freenome initiated AI-EMERGE, a clinical study for the AI-Genomics blood test has been completed, which collected samples from up to 3,000 patients in the US and Canada. The device can be configured to inject a specific dose of the hormones into the patient.

Protein 56

Protein Insulin Hormones FDA Approval 56

The Pharma Data

DECEMBER 17, 2020

Insulin is a hormone that ushers the sugars from foods into the body’s cells to be used as fuel. Because he had multiple conditions, his doctors ordered whole genome sequencing to see if they could pinpoint a root cause. Type 1 diabetes is believed to be an autoimmune disease, though the exact cause is unknown.

Insulin 52

Insulin Genetics Doctors Doctor 52

The Pharma Data

SEPTEMBER 16, 2020

Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation. GDC-0077 is our next generation investigational PI3K? Presentation #283MO (Oral), Friday, 18 September (On-demand).

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.

Research 40

Research Clinical Trials Clinical Trials Trials 40

pharmaphorum

SEPTEMBER 3, 2021

Then we go on to, we have much more subtle things where we can be producing things that can affect secretion, hormones, neurotransmission, autonomic levels, that we are able to predict those things. That’s important, but on the other hand, there is a real [musical genome] that address different aspects of the human mind, and body.

Medicine 64

Medicine Development Regulation Hormones 64

Pharmaceutical Technology

MARCH 9, 2023

Innovation S-curve for the pharmaceutical industry miRNA chemical synthesis is a key innovation area in pharmaceutical MicroRNAs (miRNAs) are a class of small, non-coding double stranded RNAs (dsRNAs) of 21-25 nucleotides in length, transcribed by the endogenous genome.

Antibody 130

Antibody Hormones DNA Genome 130

XTalks

NOVEMBER 19, 2021

Natriuretic peptides like N-terminal (NT)-pro hormone B type natriuretic peptide (NT-proBNP), or BNP, are routinely used for acute and chronic heart failure. For safety endpoints, cardiac troponin — either high sensitivity or standard — are used as markers for safety and myocardial injury and toxicity.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

Pharmaceutical Technology

MARCH 2, 2023

It was also under development for the treatment of nasopharyngeal cancer and homologous-recombination deficient (HRD) metastatic hormone refractory prostate cancer. It was also under development for the treatment of adrenocortical carcinoma, administered as a softgel capsule.

FDA Approval 100

FDA Approval Containment Development Genome 100

The Pharma Data

OCTOBER 26, 2020

50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). Final results from this study were recently presented at the ESMO Virtual Congress 2020.

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

JULY 23, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Thyroiditis can present with or without endocrinopathy.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Thyroiditis can present with or without endocrinopathy.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. Are pregnant or plan to become pregnant.

Immune Response 52

Immune Response Medicine Protein Gene 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Institute hormone replacement therapy for endocrinopathies as warranted.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Institute hormone replacement therapy for endocrinopathies as warranted.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., AZP-3601 is a parathyroid hormone (PTH) analog that targets a specific configuration of the PTH receptor, thereby inducing a prolonged increase in blood calcium levels. The patent is valid through 2038. Ltd of Japan.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52